Search 

Sanifit offers a new approach for calcification disorders. Sanifit´s lead Product (SNF472) for the reduction of calcification in dialysis patients is entering Phase I clinical trials. For the dental field OTC products were developed and are being out-licensed. The international management team has proven track record and long industry experience. Sanifit operates from Switzerland and Spain

Selcia Ltd., headquartered in Ongar, Essex, UK and with a branch in Hopkinton, Massachusetts, is a leading worldwide provider of contract research services. Selcia operates two divisions, Selcia Discovery and Selcia Radiochemistry. Whilst Radiochemistry specializes in 14C GMP radiolabelling, Selcia Discovery provides integrated small molecule drug discovery to pharmaceutical and biotech clients. Besides general medicinal chemistry and biology capabilities applicable across all target classes, Selcia Discovery has a particular strength in three unique and highly synergistic technologies: (1) medicinal chemistry on complex natural products, (2) capillary electrophoresis-based fragment and natural product screening, (3) peptidyl-prolyl isomerase targets (cyclophilins, FKBPs, Pin1, together called PPIases). Whilst relatively neglected by pharmaceutical companies in the past, understanding of the involvement of PPIases in many diseases is currently emerging. All PPIase inhibitors presently in clinical use or in development are natural products, natural product derivatives or have structures inspired by natural products.

The combination of these technologies has enabled Selcia to deliver several clinical PPIase inhibitors to clients, but has also generated IP for Selcia, which was recently demerged into a new company, Mitopharm Ltd. Mitopharm is in advanced license negotiations for a breakthrough drug in the field of acute and chronic neurodegenerative diseases. Other applications in the fields of chronic inflammatory diseases, oncology, COPD, and virus infections will be developed by Mitopharm either via investment or via joint R&D programs with pharmaceutical companies. 

Shield Therapeutics is an independent specialty pharmaceutical company, founded in 2008 with operations in Europe & US. Focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need Shield is led by Carl Sterritt, Chief Executive Officer, an experienced senior pharmaceutical executive with a track record of successful development and commercialisation of pharmaceuticals Shield has successfully raised ~$34m to fund the development of ST10 and PT20 (developed through Phosphate Therapeutics) Lead asset – ST10: Simplifying iron replacement therapy ·         Novel oral iron-based therapy with strong IPR ·         Potential to be the first simple effective oral therapy for the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD) and non-dialysis dependant chronic kidney disease (CKD) ·         Currently in Phase III trials in patients with IDA in IBD ·         Results are expected to form the basis of a marketing authorisation application (“MAA”) in 2013.  If approved, product commercialisation could commence in 2014 ·         CKD-IDA trials to follow in 2012-2013 ·         Targets potential addressable market of $5bn, with immediate IV market currently reaching  >$1bn pa   PT20: for the treatment of hyperphosphataemia ·         Novel phosphate binder to treat hyperphosphataemia in patients with pre-dialysis and dialysis-dependent CKD ·         In-licensed from Medical Research Council - agreement signed in Q3-11 ·         Early data from in vitro and in vivo trials suggests higher specificity and efficacy than current market leaders and favourable opinion received from UK-MHRA for progression to Phase II clinical trials ·         Approximately 90% of patients with kidney failure require phosphate binder therapy at some point ·         Current market size >$1bn/yr  

SuppreMol, a privately held biopharmaceutical Company, is developing novel proteins to treat autoimmune diseases. SuppreMol has developed a novel therapeutic concept for the treatment of autoimmune diseases that relies on naturally produced Fc gamma receptors (FcγRs). The Company was founded in 2002 as a spin-off from the Max Planck Institute of Biochemistry.

The Company is developing SM101 for the treatment of Primary Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) in Phase II clinical trials. SM101 is designed to be a specific, early onset, long lasting and well tolerated treatment for autoimmune diseases such as ITP, SLE, Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS).

Further building its platform of selective immunoregulators, SuppreMol is working on antibody programs targeting Fc receptors and other immunomodulatory molecules for alternative treatment strategies in autoimmune conditions.